Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial

Comparative Efficacy of Low FODMAP Plus Traditional Dietary Advice, Low-Carbohydrate Diet, and Pharmacological Treatment in Moderate-to-Severe IBS: Insights from the CARIBS Trial

The CARIBS trial shows that both low FODMAP plus traditional dietary advice and a low-carbohydrate diet outperform optimized pharmacologic treatment in reducing IBS symptom severity after 4 weeks, highlighting the importance of dietary interventions as first-line therapy.
Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Insights from a Large French Observational Study

A national French study reveals that cold agglutinin syndrome (CAS) develops about 10 days after Mycoplasma pneumoniae infection onset, often requiring ICU care and transfusions, with a generally favorable prognosis despite frequent venous thromboembolism and no clear benefit from glucocorticoid treatment.
Time-of-Day Effects of Green Tea Extract on Postprandial Glycemia and Insulinemia in Healthy Adults: Insights from a Randomized Controlled Cross-Over Trial

Time-of-Day Effects of Green Tea Extract on Postprandial Glycemia and Insulinemia in Healthy Adults: Insights from a Randomized Controlled Cross-Over Trial

Green tea extract reduces morning postprandial insulin peaks but does not alter glucose levels, with notable time-dependent effects linked to circadian rhythms influencing insulin sensitivity in healthy adults.
Impact of E-cigarette Use on Cardiovascular Risk, Lung Function, and Clinical Outcomes in Smokers: Insights from a Randomised Placebo-Controlled Trial

Impact of E-cigarette Use on Cardiovascular Risk, Lung Function, and Clinical Outcomes in Smokers: Insights from a Randomised Placebo-Controlled Trial

This review synthesizes trial evidence showing that nicotine-containing e-cigarettes modestly improve lipid profiles but cause no significant changes in lung function or other cardiovascular markers compared to cigarette substitutes in smokers reducing cigarette use.
Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-modifying therapeutic options.